Two Cases of Euglycemic Diabetic Ketosis Induced by Dapagliflozin Tablets

doi:10.19803/j.1672-8629.2021.03.13

Abstract

Abstract: Objective To remind medical staff to be more vigilant about Dapagliflozin tablets-induced euglycemic diabetic ketosis, and provide reference for safe use of Dapagliflozin tablets. Methods The process of diagnosis and treatment of 2 patients with euglycemic diabetic ketosis caused by Dapagliflozin tablets was analyzed, and the incidence and related risk factors were analyzed based on domestic and foreign literature. Results Two patients with a history of diabetic ketosis developed euglycemic diabetic ketosis 52 and 18 days after taking Dapagliflozin tablets, respectively. Dapagliflozin tablets were discontinued immediately and insulin therapy was given. The ketone bodies turned negative. Conclusion Clinicians should be alert to the risk of euglycemic diabetic ketosis induced by Dapagliflozin tablets, especially in patients with a history of diabetic ketosis.

Key words: Dapagliflozin tablets, euglycemic diabetic ketosis, adverse drug reactions

CLC Number:

R994.11

CAI Jun, WEI Jing, JI Liwei. Two Cases of Euglycemic Diabetic Ketosis Induced by Dapagliflozin Tablets[J]. Chinese Journal of Pharmacovigilance, 2021, 18(3): 271-273.

References

[1] Weng JP.New progress in sodium-glucose cotransporter-2 inhibitors[J]. Chinese Journal of Diabetes(中国糖尿病杂志), 2016, 8(11): 645-648.
[2] Ptaszynska A, Hardy E, Johnsson E, et al.Effects of dapagliflozin on cardiovascular risk factors[J]. Postgrad Med, 2013, 125(3): 181-189.
[3] Chilton R, Tikkanen I, Cannon CP, et al.Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes[J]. Diabetes Obes Metab, 2015, 17(12): 1180-1193.
[4] Baptist G.The cardiovascular benefits associated with the use of sodium-glucose cotransporter 2 inhibitors - real-world data[J]. Eur Endocrinol, 2018, 14(1): 17-23.
[5] American Diabetes Association.Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020[J]. Diabetes Care, 2020, 43: 98-110.
[6] National Medical Insurance Administration, Ministry of human resources and Social Security. List of drugs approved for negotiation of national medical insurance in 2019 [EB/OL]. (2019-11-28) [2019-12-15]. http://www.gov.cn/xinwen/2019-11/28/content_5456660. htm.
[7] Pace DJ, Dukleska K, Phillips S, et al.Euglycemic diabetic ketoacidosis due to sodium-glucose cotransporter 2 inhibitor use in two patients undergoing pancreatectomy[J]. J Pancreat Cancer, 2018, 4(1): 95-99.
[8] Chinese Society of Endocrinology. Guidelines for prevention and treatment of type 2 diabetes mellitus in China (2017 Edition)[J]. Chin J Diabetes Mellitus(中华糖尿病杂志), 2017, 10(1): 4-67.
[9] Pace DJ, Dukleska K, Phillips S, et al.Euglycemic diabetic ketoacidosis due to sodium-glucose cotransporter 2 inhibitor use in two patients undergoing pancreatectomy[J]. J Pancreat Cancer, 2018, 4(1): 95-99.
[10] Burke KR, Schumacher CA, Harpe SE.SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature[J]. Pharmacotherapy, 2017, 37(2): 187-194.
[11] Pereyra AM, Ramírez C, Román R.Euglycemic ketosis in an adolescent with type 1 diabetes on insulin and dapaglifozin: Case report[J]. Rev Chil Pediatr, 2017, 88(3):404-410.
[12] Lin YH.Sodium-glucose cotransporter-2 inhibitors induced eu-glycemic diabetic ketoacidosis: The first report in a type 2 diabetic (T2D) Taiwanese and literature review of possible pathophysio-logy and contributing factors[J]. J Formos Med Assoc, 2018, 117(9): 849-854.
[13] FDA Drug Safety Communication. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood[EB/OL]. (2015-05-15) [2019-12-15]. https://wayback.archive-it.org/7993/20170112031553/http://www.fda.gov/Drugs/DrugSafety/ucm446845. htm.
[14] FDA Drug Safety Communication. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections[EB/OL]. (2015-12-04) [2019-12-15]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about.
[15] Blau JE, Tella SH, Taylor SI, et al.Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data[J]. Diabetes Metab Res Rev, 2017, 33(8): 1-14.
[16] Zheng FY, Wu Y, Rao YF, et al.The adverse drug reaction evaluation and case analysis by using Naranjo probability scale[J]. Chin Pharm J(中国药学杂志), 2012. 47(8): 650-652.
[17] Lane S, Paskar D, Hamed S, et al.When guidelines fail: euglycemic diabetic ketoacidosis after bariatric surgery in a patient taking a sodium-glucose cotransporter-2 inhibitor: a case report[J]. A A Pract, 2018, 11(2): 46-48.